Asset
Aleniglipron
Structure Therapeutics Inc. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05893043 | phase1 | completed | 2023-04-24 | 2023-06-28 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants |
| NCT06139055 | phase1 | unknown | 2023-10-02 | 2024-03-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants |
| NCT05762471 | phase1_2 | completed | 2023-01-09 | 2024-04-11 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus |
FDA applications (0)
This company has no applications containing this asset.